Elicio Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGElicio Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 49), showing significant lag compared to the market leaders. Earnings growth of 61% provides fundamental context to the price action. Investors should exercise caution due to high volatility (76% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $11.33 | -7.79% | BELOW |
| 50 SMA | $11.39 | -8.24% | BELOW |
| 100 SMA | $9.81 | +6.51% | ABOVE |
| 150 SMA | $9.66 | +8.21% | ABOVE |
| 200 SMA | $9.88 | +5.76% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ELTX in an uptrend right now?
ELTX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ELTX overbought or oversold?
ELTX's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.
Is ELTX outperforming the market?
ELTX has a Relative Strength (RS) Rating of 49 out of 99. ELTX is currently lagging the broader market.
Where is ELTX in its 52-week range?
ELTX is trading at $10.45, which is 70% of its 52-week high ($14.93) and 56% above its 52-week low ($4.85).
How volatile is ELTX?
ELTX has a Beta of 1.64 and 52-week volatility of 76%. It's more volatile than the S&P 500 - expect bigger swings.